| P50 | author | Peter Maxwell | Q38545687 |
| | John McMurray | Q56633150 |
| | Sheldon W. Tobe | Q58091532 |
| | Maria Teresa Zanella | Q72210750 |
| | Klemens Budde | Q72992120 |
| | Svetlana Villevalde | Q85915225 |
| | Dick de Zeeuw | Q86373033 |
| | Iuliia Samoilova | Q93174405 |
| | Dalane W Kitzman | Q114291605 |
| P2093 | author name string | Hirofumi Makino | |
| | Vlado Perkovic | |
| | George Bakris | |
| | Hans-Henrik Parving | |
| | Tingting Yi | |
| | Dennis L Andress | |
| | Ricardo Correa-Rotter | |
| | Fan-Fan Hou | |
| | Hiddo J L Heerspink | |
| | Donald Kohan | |
| | Pablo E Pergola | |
| | Melissa Wigderson | |
| | Michael G Miller | |
| | Joel Z Melnick | |
| | SONAR Committees and Investigators | |
| P2860 | cites work | Avosentan reduces albumin excretion in diabetics with macroalbuminuria | Q24642372 |
| | The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy | Q28237978 |
| | Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 |
| | Avosentan for overt diabetic nephropathy | Q33702404 |
| | Endothelin and endothelin antagonists in chronic kidney disease | Q34437692 |
| | Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy | Q34726905 |
| | Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism | Q36965292 |
| | The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy | Q38778059 |
| | Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy. | Q39748148 |
| | Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 |
| | Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. | Q41173770 |
| | Management of patients with diabetes and CKD:Â conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference | Q42068388 |
| | The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. | Q43253718 |
| | The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study | Q44358769 |
| | Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 |
| | Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy | Q48098900 |
| | Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. | Q51731767 |
| | Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease | Q56987897 |
| | Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes | Q57985156 |
| | Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney disease | Q64446874 |
| | Unmet need in diabetic nephropathy: failed drugs or trials? | Q89398640 |
| | Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies | Q91009115 |
| | Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials | Q91009119 |
| P433 | issue | 10184 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| | placebo | Q269829 |
| | chronic renal insufficiency | Q736715 |
| | placebo-controlled trial | Q108853737 |
| P304 | page(s) | 1937-1947 | |
| P577 | publication date | 2019-04-14 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial | |
| P478 | volume | 393 | |